PAI-1
Inhibitory Selectivity
PAI-1 Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S9194 |
ToddalolactoneToddalolactone, a natural coumarin, inhibits the activity of recombinant human Plasminogen activator inhibitor-1 (PAI-1) in a dose-dependent manner, yielding an IC50 value of 37.31 ± 3.23 μM. |
||
| S7922 |
Tiplaxtinin (PAI-039)Tiplaxtinin(PAI-039) is an orally efficacious and selective plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 2.7 μM. |
(H) IF indicating Pcna+ and GFP+ cells after TP treatment (regime indicated at top). (I) Scatter plot of the relative number of Pcna+ cells among all wound and wound-adjacent GFP+ cells. Mean±s.d.; t-test, *P<0.05. (J) FISH combined with IHC showing that TP treatment increases cdh5 mRNA levels in GFP+ wound endocardium. (K) Scatter plot of relative red fluorescence intensity, comparing values of remote and wound endocardium (see Fig. 2F). Mean±s.d.; t-test, **P<0.01.
|
|
| S3785 |
Notoginsenoside R1Notoginsenoside R1 is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways. |
||
| S6776New |
TM5275 SodiumTM 5275 sodium is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 6.95 μM.. |
||
| S6778New |
TM5441TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 ranging between 9.7 μM and 60.3 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S9194 |
ToddalolactoneToddalolactone, a natural coumarin, inhibits the activity of recombinant human Plasminogen activator inhibitor-1 (PAI-1) in a dose-dependent manner, yielding an IC50 value of 37.31 ± 3.23 μM. |
||
| S7922 |
Tiplaxtinin (PAI-039)Tiplaxtinin(PAI-039) is an orally efficacious and selective plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 2.7 μM. |
(H) IF indicating Pcna+ and GFP+ cells after TP treatment (regime indicated at top). (I) Scatter plot of the relative number of Pcna+ cells among all wound and wound-adjacent GFP+ cells. Mean±s.d.; t-test, *P<0.05. (J) FISH combined with IHC showing that TP treatment increases cdh5 mRNA levels in GFP+ wound endocardium. (K) Scatter plot of relative red fluorescence intensity, comparing values of remote and wound endocardium (see Fig. 2F). Mean±s.d.; t-test, **P<0.01.
|
|
| S3785 |
Notoginsenoside R1Notoginsenoside R1 is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways. |
||
| S6776New |
TM5275 SodiumTM 5275 sodium is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 6.95 μM.. |
||
| S6778New |
TM5441TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 ranging between 9.7 μM and 60.3 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines. |
